

Dear Cathryn

Thank you for forwarding the SchARR Assessment Report for adjuvant capecitabine and oxaliplatin. On behalf of the ICR, our comments are as follows:

The comprehensive report produced by SchARR assesses clinical and cost-effectiveness for capecitabine and oxaliplatin (separately) as adjuvant treatment for stage III colon cancer. The cost analysis has included drug administration costs and costs of treating adverse events in an attempt to assess global cost differences between existing 5FU adjuvant regimens and the new interventions of capecitabine or oxaliplatin.

Capecitabine is estimated to be cost-saving by a total of £3320 per patient. Oxaliplatin is estimated to cost an additional £2970 per QALY gained (a relatively small cost compared to other, accepted health interventions). These figures demonstrate that both interventions are cost-effective, in addition to providing substantial clinical benefits. Capecitabine is better tolerated and more convenient to administer than intravenous 5FU/LV. Oxaliplatin has superior efficacy when added to 5FU/LV.

Kind regards

Dr Geoff Chong, MD FRACP
Locum Consultant Medical Oncologist
Royal Marsden Hospital